Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART

Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART

Understanding viral rebound in pediatric HIV-1 infection may inform the development of alternatives to lifelong antiretroviral therapy (ART) to achieve viral remission. We thus investigated viral rebound after analytical treatment interruption (ATI) in 10 infant macaques orally infected with SHIV.C....

Full description

Bibliographic Details
Main Authors:	Veronica Obregon-Perko, Katherine M. Bricker, Gloria Mensah, Ferzan Uddin, Laura Rotolo, Daryll Vanover, Yesha Desai, Philip J. Santangelo, Sherrie Jean, Jennifer S. Wood, Fawn C. Connor-Stroud, Stephanie Ehnert, Stella J. Berendam, Shan Liang, Thomas H. Vanderford, Katharine J. Bar, George M. Shaw, Guido Silvestri, Amit Kumar, Genevieve G. Fouda, Sallie R. Permar, Ann Chahroudi
Format:	Article
Language:	English
Published:	American Society for Clinical investigation 2021-12-01
Series:	JCI Insight
Subjects:	AIDS/HIV Virology
Online Access:	https://doi.org/10.1172/jci.insight.152526

Similar Items

Conditions for post-rebound SHIV control in autologous hematopoietic-stem cell transplantation
by: F. Cardozo, et al.
Published: (2019-12-01)

CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques
by: Jin Fan, et al.
Published: (2019-05-01)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
by: Hadega A Aamer, et al.
Published: (2020-08-01)

A recombinant measles virus vaccine strongly reduces SHIV viremia and virus reservoir establishment in macaques
by: Patrycja Nzounza, et al.
Published: (2021-10-01)

Differential viral rebound between lymph node and colon after treatment interruption in SHIV-infected rhesus macaques
by: D.C. Hsu, et al.
Published: (2017-12-01)

Delay in viral rebound with TLR7 agonist, N6-LS and PGT121 in SHIV-infected macaques
by: D. Hsu, et al.
Published: (2019-12-01)

Oral TLR7 agonist administration induces an immunostimulatory response in SIV-infected ART-suppressed infant rhesus macaques
by: K. Bricker, et al.
Published: (2019-07-01)

Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection
by: Alan D. Curtis, et al.
Published: (2022-02-01)

Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation
by: E Fabian Cardozo-Ojeda, et al.
Published: (2021-01-01)

HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys.
by: Brian Moldt, et al.
Published: (2022-04-01)

Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.
by: Le, T, et al.
Published: (2011)

PP 7.10 – 00088 Macrophage-Tropic HIV-1 Variants Contribute to Pediatric Rebound Viremia off ART
by: K. Ganta, et al.
Published: (2022-12-01)

Challenges and Opportunities of Therapies Targeting Early Life Immunity for Pediatric HIV Cure
by: Stella J. Berendam, et al.
Published: (2022-07-01)

Sustained SHIV reactivation by N-803 in ART-treated CD8-depleted macaques
by: J.B. McBrien, et al.
Published: (2019-07-01)

Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART® Molecules
by: Marina Tuyishime, et al.
Published: (2021-08-01)

OP 6.3 – 00150 Delivery and long-term expression of CCR5-blocking monoclonal antibody Leronlimab with AAV for ART-free remission from SHIV viremia
by: G. Webb, et al.
Published: (2022-12-01)

α4β7-blockade delays viral rebound in SHIV infected macaques treated with a combination of HIV bNAbs
by: E. Martinelli
Published: (2019-12-01)

Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques
by: Joshua A. Eudailey, et al.
Published: (2018-02-01)

Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV
by: Sandberg Johan K, et al.
Published: (2011-06-01)

TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption.
by: Denise C Hsu, et al.
Published: (2021-02-01)

Therapeutic vaccination of SIV-infected, ART-treated infant rhesus macaques using Ad48/MVA in combination with TLR-7 stimulation.
by: Katherine M Bricker, et al.
Published: (2020-10-01)

To rebound or not to rebound
by: Bethany A Stahl, et al.
Published: (2017-10-01)

Persistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant.
by: Maud Mavigner, et al.
Published: (2014-09-01)

Prenatal Immunization to Prevent Viral Disease Outcomes During Pregnancy and Early Life
by: Ria Goswami, et al.
Published: (2022-05-01)

Aging of hemp shiv used for concrete
by: Guillaume Delannoy, et al.
Published: (2018-12-01)

Bocavirus viremia
by: Pathoom Sukkaromdee, et al.
Published: (2015-01-01)

Harnessing early life immunity to develop a pediatric HIV vaccine that can protect through adolescence.
by: Ria Goswami, et al.
Published: (2020-11-01)

Proximity Ligation Assays for In Situ Detection of Innate Immune Activation: Focus on In Vitro-Transcribed mRNA
by: Emmeline L. Blanchard, et al.
Published: (2019-03-01)

Ed Howker and Shiv Malik: The Jilted Generation
by: James Wilhelm
Published: (2012-05-01)

Ed Howker and Shiv Malik: The Jilted Generation
by: James Wilhelm
Published: (2012-05-01)

Oral Vaccination Approaches for Anti-SHIV Immunity
by: Erandi Velarde de la Cruz, et al.
Published: (2021-06-01)

Rebound (reactive) thymic hyperplasia after chemotherapy in children with lymphoma
by: Ashraf Fouda, et al.
Published: (2019-09-01)

Spring Viremia of Carp
by: Barbara D. Petty, et al.
Published: (2012-09-01)

Understanding Viral and Immune Interplay During Vertical Transmission of HIV: Implications for Cure
by: Omayma Amin, et al.
Published: (2021-10-01)

New Latency Reversing Agents for HIV-1 Cure: Insights from Nonhuman Primate Models
by: Katherine M. Bricker, et al.
Published: (2021-08-01)

The Role of Maternal HIV Envelope-Specific Antibodies and Mother-to-Child Transmission Risk
by: Ayooluwa O. Douglas, et al.
Published: (2017-09-01)

Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose
by: Sholukh AM, et al.
Published: (2012-09-01)

Polymerase-tagged respiratory syncytial virus reveals a dynamic rearrangement of the ribonucleocapsid complex during infection.
by: Emmeline L Blanchard, et al.
Published: (2020-10-01)

The Roles of Host and Viral Antibody Fc Receptors in Herpes Simplex Virus (HSV) and Human Cytomegalovirus (HCMV) Infections and Immunity
by: Jennifer A. Jenks, et al.
Published: (2019-09-01)

PP 1.38 – 00212 Characterization of SIV infected mast cells in early foci of rebound after ATI and HIV infection of primary mast cells in tissue culture models reveals an important new player in viral persistence and pathogenesis
by: T. Hope, et al.
Published: (2022-12-01)